Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Nathan Green (NPI 1679563936)

Field	Value
Entity Type	Individual
Organization	Nathan Green
Address	4101 Tiger Lily Rd Ste 100
City	Lincoln
State	NE
ZIP	68516
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	October 26, 2005

Payer Source	Total Paid
Medicare	$1.1M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-focused practice: Total Medicare revenue is $1.1M and there is no Medicaid billing on file, so payer mix is single‑payer in the available data. The absence of Medicaid activity means the provider’s financial and utilization profile should be interpreted as Medicare-centric rather than dual‑payer.

Revenue is highly concentrated in a few biologic and infusion codes: the precomputed top three Medicare codes (J9299, J9271, J0897) account for 58.7% of this provider's total Medicare revenue. Those top codes individually are J9299 ($243.8K revenue, 23.0%), J9271 ($235.2K revenue, 22.2%), and J0897 ($143.6K revenue, 13.5%), highlighting a small set of high‑revenue drugs driving the practice’s Medicare income.

The overall code mix indicates an infusion‑center/medical oncology operating model: high revenue from immune checkpoint inhibitors (J9299 nivolumab and J9271 pembrolizumab) plus chemotherapy administration codes (96413, G0498) and supportive agents (J2506 pegfilgrastim, J0897 denosumab) point to outpatient cancer treatment and supportive care as the core service line. Imaging (78815, 78816) and frequent lab panels (85025, 80053) in the top codes further support active staging, monitoring, and lab management tied to oncology care.

Competitive standing for the two leading immunotherapy agents is mixed: J9299 ranks #348 of 505 providers nationally (31th percentile; typical, unremarkable volume for this code), while J9271 ranks much lower at #1653 of 1841 providers nationally (10th percentile; typical, unremarkable volume for this code). By contrast, J0897 (denosumab) ranks #1584 of 10057 providers nationally (84th percentile; typical, unremarkable volume for this code), suggesting stronger relative activity on bone‑directed/supportive therapy compared with peers.

Primary care and outpatient visit volume is notable: 99214 accounts for $85.3K (8.0% of Medicare revenue) with 1K claims and ranks #11324 of 479517 providers nationally (98th percentile; notably above typical national volume for this code). This elevated E&M footprint indicates a heavy clinic‑based evaluation and management role alongside infusion services, consistent with ongoing follow‑up and complex visit management for oncology patients.

Imaging and nuclear medicine contribute meaningfully to revenue and patient management: 78815 (PET/CT fusion) generated $87.2K (8.2% of Medicare revenue) and ranks #2527 of 6566 providers nationally (61th percentile; typical, unremarkable volume for this code), while 78816 and A9552 also appear in the top codes. These items show the practice orders or performs advanced staging/monitoring imaging as part of its oncology care pathway.

High lab and ancillary testing volumes support an active diagnostics workflow: 85025 (CBC) and 80053 (CMP) appear in the top codes and rank in the 95th and 94th percentiles respectively, while 36415 (blood draw) ranks in the 97th percentile and 83615 (LDH) ranks in the 90th percentile. The combination of frequent lab draws and panels is consistent with the monitoring needs of chemotherapy and biologic therapy patients.

The provider has longstanding enrollment and an established practice footprint: NPI enumerated 2005-10-26 (~21 years ago), which suggests operational stability and experience in oncology care. Paired with Total Medicare revenue of $1.1M, the data portray a stable, clinic‑centric oncology practice of modest Medicare scale that relies on a narrow set of high‑revenue oncology drugs and a high volume of office visits, labs, and imaging.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

64 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	10,160	$20	$243.8K
J9271	Injection, pembrolizumab, 1 mg	5,600	$40	$235.2K
J0897	Injection, denosumab, 1 mg	7,980	$20	$143.6K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	80	$1,090	$87.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,000	$90	$85.3K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	490	$80	$39.9K
J1439	Injection, ferric carboxymaltose, 1 mg	27,000	$1	$27K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	280	$90	$26K
78816	The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The…	20	$1,090	$21.8K
74177	The provider performs computed tomography of the abdomen and pelvis with contrast material to diagnose the cause of abdominal or pelvic pain or other abnormalities of the internal organs.	110	$170	$17.4K

Showing 1–10 of 64

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 64 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Nathan Green — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

64 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	27	30	14,400	$40	$671.6K
J9299	13	10	19,300	$20	$444.5K
J0897	21	200	2,040	$20	$62.7K
J2506	6	20	460	$90	$40.5K
78815	22	60	70	$380	$32.7K
J1439	14	30	25,880	$1	$26.4K
J9217	45	50	110	$130	$20.6K
J0885	11	10	3,180	$10	$19.2K
96413	28	80	60	$90	$18.2K
74177	113	160	170	$80	$15.3K

Showing 1–10 of 64

Related Providers

Other providers that share a Tax Identification Number (TIN) with Nathan Green, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bryan Medical Center	NE	General Acute Care Hospital	$0	$56.9M
Alegent Creighton Clinic	NE	Family Medicine Physician	$0	$43.2M
St. Mary's Community Hospital	NE	Rural Health Clinic/Center	$0	$3.4M
The Physician Network	NE	Family Medicine Physician	$0	$3.1M
Eric Avery	NE	Hematology & Oncology Physician	$3.1M	$0
Kailash Mosalpuria	NE	Hematology & Oncology Physician	$2.9M	$0
Chi Health Clinic Specialty, LLC	NE	Hospitalist Physician	$0	$2.6M
St. Mary's Community Hospital	NE	Critical Access Hospital	$0	$2.6M
York General Hospital	NE	Critical Access Hospital	$0	$2.4M
Madhu Midathada	NE	Hematology & Oncology Physician	$2.3M	$0

Nearby Providers

Other providers in the same ZIP code as Nathan Green, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Melvin Churchill	NE	Rheumatology Physician	$4.8M	$0
Lincoln Radiology Group PC	NE	Diagnostic Radiology Physician	$0	$4.5M
Elite Professionals Home Care LLC	NE	Home Health Agency	$0	$4.2M
Rick Chatwell	NE	Rheumatology Physician	$3.5M	$0
Lincoln Pediatric Group LLC	NE	Pediatrics Physician	$0	$2.3M
Scott Mcham	NE	Hematology & Oncology Physician	$1.9M	$0
Nebraska House Call Physicians, P.C.	NE	Internal Medicine Physician	$0	$1.7M
Steven Dunder	NE	Hematology & Oncology Physician	$1.7M	$0
Urology Surgical Center LLC	NE	Ambulatory Surgical Clinic/Center	$1.4M	$190.5K
Wallace Peterson	NE	Hematology & Oncology Physician	$1.5M	$0

Nathan Green — Billing Profile & Reimbursement Data

Sign up for Nathan Green — Billing Profile & Reimbursement Data policy alerts

Nathan Green — Billing Profile & Reimbursement Data

Sign up for Nathan Green — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References